市場調査レポート
商品コード
1375903

人工多能性幹細胞(iPS細胞)生産の市場規模、シェア、動向分析レポート:プロセス別、ワークフロー別、製品別、用途別、最終用途別、地域別、セグメント予測、2023年~2030年

Induced Pluripotent Stem Cells Production Market Size, Share & Trends Analysis Report By Process, By Workflow (Reprogramming, Cell Culture), By Product, By Application (Regenerative Medicine), By End-use, By Region, And Segment Forecasts, 2023 - 2030

出版日: | 発行: Grand View Research | ページ情報: 英文 200 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.49円
人工多能性幹細胞(iPS細胞)生産の市場規模、シェア、動向分析レポート:プロセス別、ワークフロー別、製品別、用途別、最終用途別、地域別、セグメント予測、2023年~2030年
出版日: 2023年10月09日
発行: Grand View Research
ページ情報: 英文 200 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

人工多能性幹細胞(iPS細胞)生産市場の成長と動向:

Grand View Research, Inc.の最新レポートによると、世界の人工多能性幹細胞生産市場規模は2030年までに27億6,000万米ドルに達すると推定されています。

同市場は2023年から2030年にかけてCAGR 9.3%で拡大すると予測されています。胚性幹細胞(ESC)と比較して人工多能性幹細胞(iPSC)の需要が増加していることが市場を大きく牽引しています。幹細胞に関連する倫理的問題がないこと、個別化治療が可能であること、細胞を用いた研究において柔軟性があることなどの利点が、市場成長にとって有利なシナリオを生み出しています。加えて、慢性疾患の流行も人工多能性幹細胞生産市場の成長を後押ししています。というのも、心臓病、脳卒中、糖尿病、その他多くの疾患は、iPS細胞を介在させた治療を利用することで治療できるからです。例えば、国際糖尿病連合(IDF)によると、2021年にはすでに5億3,700万人が糖尿病を患っているといいます。

COVID-19パンデミック時の研究活動の高まりは、市場にプラスの影響を与えています。パンデミックは、SARS CoV-2感染によって患者に多くの疾患が発生したため、多くの分野で研究を促進しました。例えば、2021年4月、米国の研究者たちは、COVID-19患者の最大25%が心機能障害に苦しんでいると述べた。研究論文を通じて、彼らはiPS細胞由来の心臓細胞をSARS CoV-2に暴露することで発症することを証明し、患者のヒト剖検標本からも同様の変化が確認されました。このような洞察により、人工多能性幹細胞(iPSC)を薬剤や治療法の開発プラットフォームとして利用し、COVID-19の長期的影響の管理に活用することが可能になります。

人工多能性幹細胞は、成人の体細胞から誘導され、さらにESCのような多能性を獲得するように再プログラムされた細胞です。このiPS細胞は、ESCを使用する調査にとって、倫理的に問題のない選択肢であることが証明されつつあります。ESCの作製は胚盤胞の段階で胚を破壊することになるため、倫理的な議論が最大になります。しかし、人工多能性幹細胞は、体細胞の遺伝子初期化のみを行うことで、研究におけるヒト胚の破壊に関する倫理的問題を解決しました。このことが市場の成長を促進し、創薬、疾患モデリング、毒性試験など数多くの応用をもたらしました。例えば、2021年8月、フェイト・セラピューティクス社は、臨床試験中のFT819による最初の患者の治療を発表しました。FT819はiPS細胞由来の人工CAR-T細胞療法です。また、分化可能性、自己再生可能性、免疫調節特性などのユニークな特性により、再生医療における人工多能性幹細胞の応用を模索する研究コミュニティーの注目度が高まっていることも、市場拡大の原動力となっています。

人工多能性幹細胞生産市場レポートハイライト

  • プロセス別では、手動iPSC製造プロセスが市場を独占し、2022年には77.2%の最大売上シェアを占めました。
  • ワークフロー別では、細胞培養部門が市場を席巻し、2022年の売上シェアは37.3%で最大。細胞培養ワークフローには、iPSC採取製品、拡大製品、分化製品から得られる収益が含まれるため、このセグメントの市場関連性に寄与しています。
  • 製品別では、消耗品・キットのセグメントが市場を独占し、2022年には40.3%の最大売上シェアを占めました。iPSC分野における絶え間ない研究開発活動が、さまざまな消耗品・キットの需要を牽引しています。
  • 用途別では、創薬・発見分野が2022年に43.3%の最大売上シェアを占めました。
  • 最終用途別では、バイオテクノロジー・製薬企業セグメントが2022年に59.3%の最大収益シェアで市場を独占しました。iPSCs製品とともに、さまざまなキット、消耗品、器具が入手可能であり、採用されていることが、このセグメントの収益創出を促進しています。
  • 北米が市場を独占し、2022年には40.8%の最大収益シェアを占めました。同地域における慢性疾患の罹患率の増加、発達した医療インフラ、官民双方のイニシアティブによる資金、戦略的ビジネスモデルが、同市場における収益創出を促進しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 人工多能性幹細胞生産市場の変数、動向および範囲

  • 市場系統の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 人工多能性幹細胞生産市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 人工多能性幹細胞の製造:プロセス別の推定・動向分析

  • 人工多能性幹細胞生産市場:重要なポイント
  • 人工多能性幹細胞生産市場:動向と市場シェア分析、2022年および2030年
  • 手動iPSC生産プロセス
    • 手動iPSC生産プロセス市場推計・予測、2018年から2030年まで
  • 自動iPSC生産プロセス
    • 自動iPSC生産プロセス市場推計・予測、2018年から2030年まで

第5章 人工多能性幹細胞の製造:ワークフロー別の推定・動向分析

  • 人工多能性幹細胞生産市場:重要なポイント
  • 人工多能性幹細胞生産市場:動向と市場シェア分析、2022年および2030年
  • 再プログラミング
  • 細胞培養
  • 細胞の特性評価/分析
  • エンジニアリング
  • その他

第6章 人工多能性幹細胞の生産:製品別の推定・動向分析

  • 人工多能性幹細胞生産市場:重要なポイント
  • 人工多能性幹細胞生産市場:動向と市場シェア分析、2022年および2030年
  • 機器・装置
    • 機器・装置の市場推計・予測、2018年から2030年
  • 自動化プラットフォーム
    • 自動化プラットフォーム市場推計・予測、2018年から2030年まで
  • 消耗品・キット
    • 消耗品・キットの市場推計・予測、2018年から2030年まで
    • 培地
    • キット
    • その他
  • サービス
    • サービス市場推計・予測、2018年から2030年まで

第7章 人工多能性幹細胞の生産:用途別の推定・動向分析

  • 人工多能性幹細胞生産市場:重要なポイント
  • 人工多能性幹細胞生産市場:動向と市場シェア分析、2022年および2030年
  • 創薬・発見
  • 再生医療
  • 毒物研究
  • その他

第8章 人工多能性幹細胞の生産:最終用途別の推定・動向分析

  • 人工多能性幹細胞生産市場:重要なポイント
  • 人工多能性幹細胞生産市場:動向と市場シェア分析、2022年および2030年
  • 研究・学術機関
    • 研究・学術機関の市場推計・予測と2018年から2030年
  • バイオテクノロジー・製薬企業
    • バイオテクノロジー・製薬企業の市場推計・予測、2018年から2030年まで
  • 病院・診療所
    • 病院・診療所の市場推計・予測、2018年から2030年まで

第9章 人工多能性幹細胞の生産:地域別の推定・動向分析

  • 地域別の展望
  • 地域別の人工多能性幹細胞生産市場:主要市場のポイント
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第10章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 市場参入企業の分類
    • Lonza
    • Axol Biosciences Ltd.
    • Evotec Se
    • Hitachi Ltd.
    • Reprocells Inc.
    • Fate Therapeutics
    • Thermo Fisher Scientific, Inc.
    • Merck Kgaa
    • StemCellsFactory III
    • Applied StemCells, Inc.
図表

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America induced pluripotent stem cells production market, by process, 2018 - 2030 (USD Million)
  • Table 3 North America induced pluripotent stem cells production market, by workflow, 2018 - 2030 (USD Million)
  • Table 4 North America induced pluripotent stem cells production market, by product, 2018 - 2030 (USD Million)
  • Table 5 North America induced pluripotent stem cells production market, by application, 2018 - 2030 (USD Million)
  • Table 6 North America induced pluripotent stem cells production market, by end use, 2018 - 2030 (USD Million)
  • Table 7 North America induced pluripotent stem cells production market, by region, 2018 - 2030 (USD Million)
  • Table 8 U.S. induced pluripotent stem cells production market, by process, 2018 - 2030 (USD Million)
  • Table 9 U.S. induced pluripotent stem cells production market, by workflow, 2018 - 2030 (USD Million)
  • Table 10 U.S. induced pluripotent stem cells production market, by product, 2018 - 2030 (USD Million)
  • Table 11 U.S. induced pluripotent stem cells production market, by application, 2018 - 2030 (USD Million)
  • Table 12 U.S. induced pluripotent stem cells production market, by end use, 2018 - 2030 (USD Million)
  • Table 13 Canada induced pluripotent stem cells production market, by process, 2018 - 2030 (USD Million)
  • Table 14 Canada induced pluripotent stem cells production market, by workflow, 2018 - 2030 (USD Million)
  • Table 15 Canada induced pluripotent stem cells production market, by product, 2018 - 2030 (USD Million)
  • Table 16 Canada induced pluripotent stem cells production market, by application, 2018 - 2030 (USD Million)
  • Table 17 Canada induced pluripotent stem cells production market, by end use, 2018 - 2030 (USD Million)
  • Table 18 Europe induced pluripotent stem cells production market, by process, 2018 - 2030 (USD Million)
  • Table 19 Europe induced pluripotent stem cells production market, by workflow, 2018 - 2030 (USD Million)
  • Table 20 Europe induced pluripotent stem cells production market, by product, 2018 - 2030 (USD Million)
  • Table 21 Europe induced pluripotent stem cells production market, by application, 2018 - 2030 (USD Million)
  • Table 22 Europe induced pluripotent stem cells production market, by end use, 2018 - 2030 (USD Million)
  • Table 23 Europe induced pluripotent stem cells production market, by region, 2018 - 2030 (USD Million)
  • Table 24 Germany induced pluripotent stem cells production market, by process, 2018 - 2030 (USD Million)
  • Table 25 Germany induced pluripotent stem cells production market, by workflow, 2018 - 2030 (USD Million)
  • Table 26 Germany induced pluripotent stem cells production market, by product, 2018 - 2030 (USD Million)
  • Table 27 Germany induced pluripotent stem cells production market, by application, 2018 - 2030 (USD Million)
  • Table 28 Germany induced pluripotent stem cells production market, by end use, 2018 - 2030 (USD Million)
  • Table 29 UK induced pluripotent stem cells production market, by process, 2018 - 2030 (USD Million)
  • Table 30 UK induced pluripotent stem cells production market, by workflow, 2018 - 2030 (USD Million)
  • Table 31 UK induced pluripotent stem cells production market, by product, 2018 - 2030 (USD Million)
  • Table 32 UK induced pluripotent stem cells production market, by application, 2018 - 2030 (USD Million)
  • Table 33 UK induced pluripotent stem cells production market, by end use, 2018 - 2030 (USD Million)
  • Table 34 France induced pluripotent stem cells production market, by process, 2018 - 2030 (USD Million)
  • Table 35 France induced pluripotent stem cells production market, by workflow, 2018 - 2030 (USD Million)
  • Table 36 France induced pluripotent stem cells production market, by product, 2018 - 2030 (USD Million)
  • Table 37 France induced pluripotent stem cells production market, by application, 2018 - 2030 (USD Million)
  • Table 38 France induced pluripotent stem cells production market, by end use, 2018 - 2030 (USD Million)
  • Table 39 Italy induced pluripotent stem cells production market, by process, 2018 - 2030 (USD Million)
  • Table 40 Italy induced pluripotent stem cells production market, by workflow, 2018 - 2030 (USD Million)
  • Table 41 Italy induced pluripotent stem cells production market, by product, 2018 - 2030 (USD Million)
  • Table 42 Italy induced pluripotent stem cells production market, by application, 2018 - 2030 (USD Million)
  • Table 43 Italy induced pluripotent stem cells production market, by end use, 2018 - 2030 (USD Million)
  • Table 44 Spain induced pluripotent stem cells production market, by process, 2018 - 2030 (USD Million)
  • Table 45 Spain induced pluripotent stem cells production market, by workflow, 2018 - 2030 (USD Million)
  • Table 46 Spain induced pluripotent stem cells production market, by product, 2018 - 2030 (USD Million)
  • Table 47 Spain induced pluripotent stem cells production market, by application, 2018 - 2030 (USD Million)
  • Table 48 Spain induced pluripotent stem cells production market, by end use, 2018 - 2030 (USD Million)
  • Table 49 Sweden induced pluripotent stem cells production market, by process, 2018 - 2030 (USD Million)
  • Table 50 Sweden induced pluripotent stem cells production market, by workflow, 2018 - 2030 (USD Million)
  • Table 51 Sweden induced pluripotent stem cells production market, by product, 2018 - 2030 (USD Million)
  • Table 52 Sweden induced pluripotent stem cells production market, by application, 2018 - 2030 (USD Million)
  • Table 53 Sweden induced pluripotent stem cells production market, by end use, 2018 - 2030 (USD Million)
  • Table 54 Norway induced pluripotent stem cells production market, by process, 2018 - 2030 (USD Million)
  • Table 55 Norway induced pluripotent stem cells production market, by workflow, 2018 - 2030 (USD Million)
  • Table 56 Norway induced pluripotent stem cells production market, by product, 2018 - 2030 (USD Million)
  • Table 57 Norway induced pluripotent stem cells production market, by application, 2018 - 2030 (USD Million)
  • Table 58 Norway induced pluripotent stem cells production market, by end use, 2018 - 2030 (USD Million)
  • Table 59 Norway induced pluripotent stem cells production market, by process, 2018 - 2030 (USD Million)
  • Table 60 Denmark induced pluripotent stem cells production market, by workflow, 2018 - 2030 (USD Million)
  • Table 61 Denmark induced pluripotent stem cells production market, by product, 2018 - 2030 (USD Million)
  • Table 62 Denmark induced pluripotent stem cells production market, by application, 2018 - 2030 (USD Million)
  • Table 63 Denmark induced pluripotent stem cells production market, by end use, 2018 - 2030 (USD Million)
  • Table 64 Asia Pacific induced pluripotent stem cells production market, by process, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific induced pluripotent stem cells production market, by workflow, 2018 - 2030 (USD Million)
  • Table 66 Asia Pacific induced pluripotent stem cells production market, by product, 2018 - 2030 (USD Million)
  • Table 67 Asia Pacific induced pluripotent stem cells production market, by application, 2018 - 2030 (USD Million)
  • Table 68 Asia Pacific induced pluripotent stem cells production market, by end use, 2018 - 2030 (USD Million)
  • Table 69 Asia Pacific induced pluripotent stem cells production market, by region, 2018 - 2030 (USD Million)
  • Table 70 China induced pluripotent stem cells production market, by process, 2018 - 2030 (USD Million)
  • Table 71 China induced pluripotent stem cells production market, by workflow, 2018 - 2030 (USD Million)
  • Table 72 China induced pluripotent stem cells production market, by product, 2018 - 2030 (USD Million)
  • Table 73 China induced pluripotent stem cells production market, by application, 2018 - 2030 (USD Million)
  • Table 74 China induced pluripotent stem cells production market, by end use, 2018 - 2030 (USD Million)
  • Table 75 Japan induced pluripotent stem cells production market, by process, 2018 - 2030 (USD Million)
  • Table 76 Japan induced pluripotent stem cells production market, by workflow, 2018 - 2030 (USD Million)
  • Table 77 Japan induced pluripotent stem cells production market, by product, 2018 - 2030 (USD Million)
  • Table 78 Japan induced pluripotent stem cells production market, by application, 2018 - 2030 (USD Million)
  • Table 79 Japan induced pluripotent stem cells production market, by end use, 2018 - 2030 (USD Million)
  • Table 80 India induced pluripotent stem cells production market, by process, 2018 - 2030 (USD Million)
  • Table 81 India induced pluripotent stem cells production market, by workflow, 2018 - 2030 (USD Million)
  • Table 82 India induced pluripotent stem cells production market, by product, 2018 - 2030 (USD Million)
  • Table 83 India induced pluripotent stem cells production market, by application, 2018 - 2030 (USD Million)
  • Table 84 India induced pluripotent stem cells production market, by end use, 2018 - 2030 (USD Million)
  • Table 85 Australia induced pluripotent stem cells production market, by process, 2018 - 2030 (USD Million)
  • Table 86 Australia induced pluripotent stem cells production market, by workflow, 2018 - 2030 (USD Million)
  • Table 87 Australia induced pluripotent stem cells production market, by product, 2018 - 2030 (USD Million)
  • Table 88 Australia induced pluripotent stem cells production market, by application, 2018 - 2030 (USD Million)
  • Table 89 Australia induced pluripotent stem cells production market, by end use, 2018 - 2030 (USD Million)
  • Table 90 Thailand induced pluripotent stem cells production market, by process, 2018 - 2030 (USD Million)
  • Table 91 Thailand induced pluripotent stem cells production market, by workflow, 2018 - 2030 (USD Million)
  • Table 92 Thailand induced pluripotent stem cells production market, by product, 2018 - 2030 (USD Million)
  • Table 93 Thailand induced pluripotent stem cells production market, by application, 2018 - 2030 (USD Million)
  • Table 94 Thailand induced pluripotent stem cells production market, by end use, 2018 - 2030 (USD Million)
  • Table 95 South Korea induced pluripotent stem cells production market, by process, 2018 - 2030 (USD Million)
  • Table 96 South Korea induced pluripotent stem cells production market, by workflow, 2018 - 2030 (USD Million)
  • Table 97 South Korea induced pluripotent stem cells production market, by product, 2018 - 2030 (USD Million)
  • Table 98 South Korea induced pluripotent stem cells production market, by application, 2018 - 2030 (USD Million)
  • Table 99 South Korea induced pluripotent stem cells production market, by end use, 2018 - 2030 (USD Million)
  • Table 100 Latin America induced pluripotent stem cells production market, by process, 2018 - 2030 (USD Million)
  • Table 101 Latin America induced pluripotent stem cells production market, by workflow, 2018 - 2030 (USD Million)
  • Table 102 Latin America induced pluripotent stem cells production market, by product, 2018 - 2030 (USD Million)
  • Table 103 Latin America induced pluripotent stem cells production market, by application, 2018 - 2030 (USD Million)
  • Table 104 Latin America induced pluripotent stem cells production market, by end use, 2018 - 2030 (USD Million)
  • Table 105 Latin America induced pluripotent stem cells production market, by region, 2018 - 2030 (USD Million)
  • Table 106 Brazil induced pluripotent stem cells production market, by process, 2018 - 2030 (USD Million)
  • Table 107 Brazil induced pluripotent stem cells production market, by workflow, 2018 - 2030 (USD Million)
  • Table 108 Brazil induced pluripotent stem cells production market, by product, 2018 - 2030 (USD Million)
  • Table 109 Brazil induced pluripotent stem cells production market, by application, 2018 - 2030 (USD Million)
  • Table 110 Brazil induced pluripotent stem cells production market, by end use, 2018 - 2030 (USD Million)
  • Table 111 Mexico induced pluripotent stem cells production market, by process, 2018 - 2030 (USD Million)
  • Table 112 Mexico induced pluripotent stem cells production market, by workflow, 2018 - 2030 (USD Million)
  • Table 113 Mexico induced pluripotent stem cells production market, by product, 2018 - 2030 (USD Million)
  • Table 114 Mexico induced pluripotent stem cells production market, by application, 2018 - 2030 (USD Million)
  • Table 115 Mexico induced pluripotent stem cells production market, by end use, 2018 - 2030 (USD Million)
  • Table 116 Argentina induced pluripotent stem cells production market, by process, 2018 - 2030 (USD Million)
  • Table 117 Argentina induced pluripotent stem cells production market, by workflow, 2018 - 2030 (USD Million)
  • Table 118 Argentina induced pluripotent stem cells production market, by product, 2018 - 2030 (USD Million)
  • Table 119 Argentina induced pluripotent stem cells production market, by application, 2018 - 2030 (USD Million)
  • Table 120 Argentina induced pluripotent stem cells production market, by end use, 2018 - 2030 (USD Million)
  • Table 121 Middle East and Africa induced pluripotent stem cells production market, by process, 2018 - 2030 (USD Million)
  • Table 122 Middle East and Africa induced pluripotent stem cells production market, by workflow, 2018 - 2030 (USD Million)
  • Table 123 Middle East and Africa induced pluripotent stem cells production market, by product, 2018 - 2030 (USD Million)
  • Table 124 Middle East and Africa induced pluripotent stem cells production market, by application, 2018 - 2030 (USD Million)
  • Table 125 Middle East and Africa induced pluripotent stem cells production market, by end use, 2018 - 2030 (USD Million)
  • Table 126 Middle East and Africa induced pluripotent stem cells production market, by region, 2018 - 2030 (USD Million)
  • Table 127 South Africa induced pluripotent stem cells production market, by process, 2018 - 2030 (USD Million)
  • Table 128 South Africa induced pluripotent stem cells production market, by workflow, 2018 - 2030 (USD Million)
  • Table 129 South Africa induced pluripotent stem cells production market, by product, 2018 - 2030 (USD Million)
  • Table 130 South Africa induced pluripotent stem cells production market, by application, 2018 - 2030 (USD Million)
  • Table 131 South Africa induced pluripotent stem cells production market, by end use, 2018 - 2030 (USD Million)
  • Table 132 Saudi Arabia induced pluripotent stem cells production market, by process, 2018 - 2030 (USD Million)
  • Table 133 Saudi Arabia induced pluripotent stem cells production market, by workflow, 2018 - 2030 (USD Million)
  • Table 134 Saudi Arabia induced pluripotent stem cells production market, by product, 2018 - 2030 (USD Million)
  • Table 135 Saudi Arabia induced pluripotent stem cells production market, by application, 2018 - 2030 (USD Million)
  • Table 136 Saudi Arabia induced pluripotent stem cells production market, by end use, 2018 - 2030 (USD Million)
  • Table 137 UAE induced pluripotent stem cells production market, by process, 2018 - 2030 (USD Million)
  • Table 138 UAE induced pluripotent stem cells production market, by workflow, 2018 - 2030 (USD Million)
  • Table 139 UAE induced pluripotent stem cells production market, by product, 2018 - 2030 (USD Million)
  • Table 140 UAE induced pluripotent stem cells production market, by application, 2018 - 2030 (USD Million)
  • Table 141 UAE induced pluripotent stem cells production market, by end use, 2018 - 2030 (USD Million)
  • Table 142 Kuwait induced pluripotent stem cells production market, by process, 2018 - 2030 (USD Million)
  • Table 143 Kuwait induced pluripotent stem cells production market, by workflow, 2018 - 2030 (USD Million)
  • Table 144 Kuwait induced pluripotent stem cells production market, by product, 2018 - 2030 (USD Million)
  • Table 145 Kuwait induced pluripotent stem cells production market, by application, 2018 - 2030 (USD Million)
  • Table 146 Kuwait induced pluripotent stem cells production market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 Induced pluripotent stem cells production: Market outlook
  • Fig. 8 Induced pluripotent stem cells production: Competitive insights
  • Fig. 9 Parent market outlook
  • Fig. 10 Related/ancillary market outlook
  • Fig. 11 Penetration and growth prospect mapping
  • Fig. 12 Industry value chain analysis
  • Fig. 13 Induced pluripotent stem cells production market driver impact
  • Fig. 14 Induced pluripotent stem cells production market restraint impact
  • Fig. 15 Induced pluripotent stem cells production market strategic initiatives analysis
  • Fig. 16 Induced pluripotent stem cells production market: Process movement analysis
  • Fig. 17 Induced pluripotent stem cells production market: Process outlook and key takeaways
  • Fig. 18 Manual iPSC production process estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Automated iPSC production process estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Induced pluripotent stem cells production market: Workflow movement analysis
  • Fig. 21 Induced pluripotent stem cells production market: Workflow outlook and key takeaways
  • Fig. 22 Reprogramming market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Cell culture market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Cell characterization / analysis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Engineering market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Induced pluripotent stem cells production market: Product movement analysis
  • Fig. 28 Induced pluripotent stem cells production market: Product outlook and key takeaways
  • Fig. 29 Instruments/ devices market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Automated platforms market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Consumables & kits market estimates and forecasts, 2018 - 2030
  • Fig. 32 Media market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Kits market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Induced pluripotent stem cells production market: Application movement analysis
  • Fig. 37 Induced pluripotent stem cells production market: Application outlook and key takeaways
  • Fig. 38 Drug development and discovery market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Regenerative medicine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Toxicology studies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Others market estimates and forecasts, 2018 - 2030
  • Fig. 42 Induced pluripotent stem cells production market: End use movement analysis
  • Fig. 43 Induced pluripotent stem cells production market: End use outlook and key takeaways
  • Fig. 44 Research & academic institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Biotechnology & pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Hospitals & clinics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Global Induced pluripotent stem cells production market: Regional movement analysis
  • Fig. 48 Global Induced pluripotent stem cells production market: Regional outlook and key takeaways
  • Fig. 49 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68039-549-7

Induced Pluripotent Stem Cells Production Market Growth & Trends:

The global induced pluripotent stem cells production market size is estimated to reach USD 2.76 billion by 2030, according to a new report by Grand View Research, Inc.. The market is expected to expand at a CAGR of 9.3% from 2023 to 2030. The increase in demand for induced pluripotent stem cells (iPSCs) in comparison to Embryonic Stem Cells (ESCs) has offered a significant drive to the market. Advantages such as no stem cell-related ethical issues, personalized treatment, and flexibility during cell-based research have created a favorable scenario for market growth. In addition, the prevalence of chronic disorders is also driving the growth of the induced pluripotent stem cells production market, as conditions like heart disease, stroke, diabetes, and many more can be treated by utilizing iPSCs-mediated therapy. For example, according to the International Diabetes Federation (IDF), 537 million people are already living with diabetes in 2021.

The rising research activities during COVID-19 pandemic have positively impacted the market. The pandemic fueled research in many fields as the SARS CoV-2 infection resulted in many diseases in the patients. For instance, in April 2021, researchers from USA stated that up to 25% of COVID-19 patients suffered cardiac dysfunction. Through their research article, they demonstrated the pathogenesis via exposure of iPSCs-derived cardiac cells to SARS CoV-2, and similar alterations were confirmed from human autopsy specimens of the patients. Such insights allow the use of induced pluripotent stem cells (iPSCs) as drug or therapy development platforms and their utilization in the management of the long-term effects of COVID-19.

Induced pluripotent stem cells are cells that are derived from adult somatic cells and then further reprogrammed to obtain the pluripotency as that of ESCs. These iPSCs are proving to be an ethically uncomplicated alternative for research that involves ESCs. The derivation of the ESCs is associated with the destruction of an embryo at the blastocyte stage, which has led to a maximum number of ethical debates. However, induced pluripotent stem cells have solved the ethical issue over the destruction of human embryos in research by involving only the genetic reprogramming of somatic cells. This has propelled the market growth and resulted in numerous applications including drug discovery, disease modeling, toxicology testing, and many others. For instance, in August 2021, Fate Therapeutics announced the treatment of the first patient with FT819 during clinical trials. FT819 is an engineered CAR-T cell therapy that is derived from iPSCs. Also, the rising focus of the research community on exploring applications of induced pluripotent stem cells in regenerative medicine due to their unique characteristics such as differential potential, self-renewable, immunomodulatory properties, and others; is set to drive the market expansion.

Induced Pluripotent Stem Cells Production Market Report Highlights:

  • By process, the manual iPSC production process segment dominated the market and accounted for the largest revenue share of 77.2% in 2022.
  • By workflow, the cell culture segment dominated the market with the largest revenue share of 37.3% in 2022. Cell culture workflow is inclusive of revenues generated from iPSC harvest products, expansion products, and differentiation products; thus contributing to the market relevance of this segment.
  • By product, the consumables and kits segment dominated the market and accounted for the largest revenue share of 40.3% in 2022. The never-ceasing research and development activities in the iPSCs space are driving the demand for various consumables & kits.
  • By application, drug development & discovery segment dominated the market with the largest revenue share of 43.3% in 2022.
  • By end-user, the biotechnology and pharmaceutical companies segment dominated the market with the largest revenue share of 59.3% in 2022. The availability and adoption of various kits, consumables, and instruments along with iPSCs products are driving the revenue generation in this segment.
  • North America dominated the market and accounted for the largest revenue share of 40.8% in 2022. The growing incidence of chronic diseases in this region, developed healthcare infrastructure, funds from private & government initiatives, and strategic business models are driving the revenue generation in the marketspace.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Process
    • 1.1.2. Workflow
    • 1.1.3. Product
    • 1.1.4. Application
    • 1.1.5. End use
    • 1.1.6. Regional scope
    • 1.1.7. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Process outlook
    • 2.2.2. Workflow outlook
    • 2.2.3. Product outlook
    • 2.2.4. Application outlook
    • 2.2.5. End use outlook
    • 2.2.6. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Induced Pluripotent Stem Cells Production Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Induced Pluripotent Stem Cells Production Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Induced Pluripotent Stem Cells Production: Process Estimates & Trend Analysis

  • 4.1. Induced Pluripotent Stem Cells Production Market: Key Takeaways
  • 4.2. Induced Pluripotent Stem Cells Production Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Manual iPSC Production Process
    • 4.3.1. Manual iPSC production process market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Automated iPSC Production Process
    • 4.4.1. Automated iPSC production process market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Induced Pluripotent Stem Cells Production: Workflow Estimates & Trend Analysis

  • 5.1. Induced Pluripotent Stem Cells Production Market: Key Takeaways
  • 5.2. Induced Pluripotent Stem Cells Production Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Reprogramming
    • 5.3.1. Reprogramming market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Cell Culture
    • 5.4.1. Cell culture market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Cell Characterization / Analysis
    • 5.5.1. Cell characterization / analysis market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Engineering
    • 5.6.1. Engineering market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Induced Pluripotent Stem Cells Production: Product Estimates & Trend Analysis

  • 6.1. Induced Pluripotent Stem Cells Production Market: Key Takeaways
  • 6.2. Induced Pluripotent Stem Cells Production Market: Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Instruments/ Devices
    • 6.3.1. Instruments/ devices market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4. Automated Platforms
    • 6.4.1. Automated platforms market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Consumables & Kits
    • 6.5.1. Consumables & kits market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.2. Media
      • 6.5.2.1. Media market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.3. Kits
      • 6.5.3.1. Kits market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.4. Others
      • 6.5.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6. Services
    • 6.6.1. Services market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Induced Pluripotent Stem Cells Production: Application Estimates & Trend Analysis

  • 7.1. Induced Pluripotent Stem Cells Production Market: Key Takeaways
  • 7.2. Induced Pluripotent Stem Cells Production Market: Movement & Market Share Analysis, 2022 & 2030
  • 7.3. Drug Development & Discovery
    • 7.3.1. Drug development & discovery market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4. Regenerative Medicine
    • 7.4.1. Regenerative medicine market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5. Toxicology Studies
    • 7.5.1. Toxicology studies market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6. Others
    • 7.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Induced Pluripotent Stem Cells Production: End Use Estimates & Trend Analysis

  • 8.1. Induced Pluripotent Stem Cells Production Market: Key Takeaways
  • 8.2. Induced Pluripotent Stem Cells Production Market: Movement & Market Share Analysis, 2022 & 2030
  • 8.3. Research & Academic Institutes
    • 8.3.1. Research & academic institutes market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4. Biotechnology & Pharmaceutical Companies
    • 8.4.1. Biotechnology & pharmaceutical companies market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5. Hospitals & Clinics
    • 8.5.1. Hospitals & clinics market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Induced Pluripotent Stem Cells Production: Regional Estimates & Trend Analysis

  • 9.1. Regional Outlook
  • 9.2. Induced Pluripotent Stem Cells Production Market by Region: Key Marketplace Takeaway
  • 9.3. North America
    • 9.3.1. North America market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 9.3.2. U.S.
      • 9.3.2.1. U.S. market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 9.3.3. Canada
      • 9.3.3.1. Canada market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.4. Europe
    • 9.4.1. Europe market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 9.4.2. UK
      • 9.4.2.1. UK market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 9.4.3. Germany
      • 9.4.3.1. Germany market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 9.4.4. France
      • 9.4.4.1. France market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 9.4.5. Italy
      • 9.4.5.1. Italy market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 9.4.6. Spain
      • 9.4.6.1. Spain market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 9.4.7. Sweden
      • 9.4.7.1. Sweden market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 9.4.8. Norway
      • 9.4.8.1. Norway market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 9.4.9. Denmark
      • 9.4.9.1. Denmark market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.5. Asia Pacific
    • 9.5.1. Asia Pacific market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 9.5.2. Japan
      • 9.5.2.1. Japan market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 9.5.3. China
      • 9.5.3.1. China market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 9.5.4. India
      • 9.5.4.1. India market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 9.5.5. Australia
      • 9.5.5.1. Australia market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 9.5.6. Thailand
      • 9.5.6.1. Thailand market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 9.5.7. South Korea
      • 9.5.7.1. South Korea market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.6. Latin America
    • 9.6.1. Latin America market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 9.6.2. Brazil
      • 9.6.2.1. Brazil market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 9.6.3. Mexico
      • 9.6.3.1. Mexico market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 9.6.4. Argentina
      • 9.6.4.1. Argentina market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.7. MEA
    • 9.7.1. MEA market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 9.7.2. Saudi Arabia
      • 9.7.2.1. Saudi Arabia market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 9.7.3. South Africa
      • 9.7.3.1. South Africa market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 9.7.4. UAE
      • 9.7.4.1. UAE market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 9.7.5. Kuwait
      • 9.7.5.1. Kuwait market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 10.2. Market Participant Categorization
    • 10.2.1. Lonza
      • 10.2.1.1. Company overview
      • 10.2.1.2. Financial performance
      • 10.2.1.3. Product benchmarking
      • 10.2.1.4. Strategic initiatives
    • 10.2.2. Axol Biosciences Ltd.
      • 10.2.2.1. Company overview
      • 10.2.2.2. Financial performance
      • 10.2.2.3. Product benchmarking
      • 10.2.2.4. Strategic initiatives
    • 10.2.3. Evotec Se
      • 10.2.3.1. Company overview
      • 10.2.3.2. Financial performance
      • 10.2.3.3. Product benchmarking
      • 10.2.3.4. Strategic initiatives
    • 10.2.4. Hitachi Ltd.
      • 10.2.4.1. Company overview
      • 10.2.4.2. Financial performance
      • 10.2.4.3. Product benchmarking
      • 10.2.4.4. Strategic initiatives
    • 10.2.5. Reprocells Inc.
      • 10.2.5.1. Company overview
      • 10.2.5.2. Financial performance
      • 10.2.5.3. Product benchmarking
      • 10.2.5.4. Strategic initiatives
    • 10.2.6. Fate Therapeutics
      • 10.2.6.1. Company overview
      • 10.2.6.2. Financial performance
      • 10.2.6.3. Product benchmarking
      • 10.2.6.4. Strategic initiatives
    • 10.2.7. Thermo Fisher Scientific, Inc.
      • 10.2.7.1. Company overview
      • 10.2.7.2. Financial performance
      • 10.2.7.3. Product benchmarking
      • 10.2.7.4. Strategic initiatives
    • 10.2.8. Merck Kgaa
      • 10.2.8.1. Company overview
      • 10.2.8.2. Financial performance
      • 10.2.8.3. Product benchmarking
      • 10.2.8.4. Strategic initiatives
    • 10.2.9. StemCellsFactory III
      • 10.2.9.1. Company overview
      • 10.2.9.2. Financial performance
      • 10.2.9.3. Product benchmarking
      • 10.2.9.4. Strategic initiatives
    • 10.2.10. Applied StemCells, Inc.
      • 10.2.10.1. Company overview
      • 10.2.10.2. Financial performance
      • 10.2.10.3. Product benchmarking
      • 10.2.10.4. Strategic initiatives